Close Menu
Glaxo and Galapagos Ink Anti-Infective Development Deal
 
GlaxoSmithKline and Galapagos this week said that they have entered into a multi-year, strategic alliance to develop novel anti-infective drug candidates.
 
GSK will participate in the alliance through its Infectious Diseases Center of Excellence for Drug Discovery. Under the terms of the agreement, Galapagos will grant GSK options to license product candidates that are directed against up to six anti-infective discovery targets. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.